Prevention of the cryptic epitope SLAYGLR within osteopontin does not influence susceptibility to Candida albicans infection.
The effect of an antiosteopontin antibody (M5 Ab) reacting with the SLAYGLR sequence within osteopontin on the host susceptibility to infection was investigated in a murine model of disseminated candidiasis. The treatment with anti-tumor necrosis factor alpha antibody enhanced fungal infection, while the treatment with M5 Ab did not affect the infection.
Fermentation Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan. ikuko.sato@jp.astellas.com
Ikuko
I
Sato
Nobuchika
N
Yamamoto
Harumi
H
Yamazaki
Seiji
S
Hashimoto
Motohiro
M
Hino
Fumihiko
F
Sakai
Akihiko
A
Fujie
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002176:Candida albicans / Q000472:pathogenicity*; D002177:Candidiasis / Q000276:immunology / Q000382:microbiology / Q000503:physiopathology / Q000628:therapy*; D015169:Colony Count, Microbial; D004195:Disease Models, Animal; D000939:Epitopes / Q000276:immunology*; D005260:Female; D006801:Humans; D007668:Kidney / Q000382:microbiology; D051379:Mice; D008813:Mice, Inbred ICR; D053495:Osteopontin; D012795:Sialoglycoproteins / Q000737:chemistry* / Q000276:immunology*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000911:Antibodies, Monoclonal; D000939:Epitopes; C506895:SPP1 protein, human; D012795:Sialoglycoproteins; C506896:Spp1 protein, mouse; D014409:Tumor Necrosis Factor-alpha; D053495:Osteopontin